Chronic Spontaneous Urticaria and Chronic Venous Insufficiency Market

The Chronic Spontaneous Urticaria Market Size in the 7MM was ~USD 2000 million in 2023, expected to grow at a significant CAGR by 2034, per DelveInsight.

DelveInsight’s "Chronic Venous Insufficiency Market Insight, Epidemiology, and Market Forecast – 2034" report provides an in-depth analysis of Chronic Venous Insufficiency (CVI), including historical and forecasted epidemiology, market trends in the US, EU4 (Germany, France, Italy, Spain), UK, and Japan.

Discover which therapies are expected to grab the Chronic Venous Insufficiency Market Share @ Chronic Venous Insufficiency Market Outlook

In the 7MM, the US had the highest CVI prevalent cases: nearly 6.2 million in 2020. Total 7MM prevalent cases: 463 million in 2020. Among EU4 and UK, Germany led, followed by the UK; Spain had the fewest. Per DelveInsight’s CVD epidemiology model, C1 stage showed the highest diagnosed prevalence in the US. Leading CVI companies: Verigraft AB, enVVeno Medical Corporation, Theraclion, and others. Promising pipeline therapies: Coumarin/troxerutin, Antistax film coated tablets, Venocur Triplex®, Antistax®, Detralex, V0322 BC, Esarin Gel, 0.1% TR 987, Sirolimus, and others.

Stay ahead in the Chronic Venous Insufficiency Therapeutics Market with DelveInsight's Strategic Report @ Chronic Venous Insufficiency Treatment Market

CVI prevalence was calculated for adults, adjusted for diagnosis rates to estimate diagnosed cases. CVI-specific cases (stages C3–C6 per CEAP classification) were segmented by gender across the US, EU4, UK, and Japan (2020–2034).

Download the report to understand which factors are driving Chronic Venous Insufficiency Epidemiology trends @ Chronic Venous Insufficiency Prevalence

Venclose System (BD): A radiofrequency ablation system with Maven Catheter and digiRF Generator for endovenous treatment, causing vein occlusion via controlled RF energy, followed by fibrosis and resorption. Includes optional foot pedal.

P-TEV (Verigraft AB): An advanced therapy using decellularized allogeneic vein scaffolds populated with autologous patient blood components, offering an alternative to grafts without immunosuppression.

To learn more about Chronic Venous Insufficiency Treatment guidelines, visit @ Chronic Venous Insufficiency Clinical Trials Assessment

CVI Companies: Verigraft AB, enVVeno Medical Corporation, Theraclion, and others.

In the pipeline, SONOVEIN (Theraclion) is a robotic HIFU-based echotherapy device for non-invasive vein treatment, evaluated in the VEINRESET study (12-month follow-up results expected by 2025; FDA approval filing planned for H2 2025).

Learn more about the FDA-approved drugs for Chronic Venous Insufficiency @ Drugs for Chronic Venous Insufficiency Treatment

Japan: Taiho Pharmaceutical (Otsuka Group) develops TAS5315 (Phase 2 completed + Phase 1), an oral BTK inhibitor for antihistamine-refractory CSU, showing UAS7 reduction and emerging as a non-IgE disease-modifying therapy. Kyowa Kirin sponsors Omalizumab (Phase 3/post-marketing), the first biologic approved for CSU in Japan (PMDA), with extensive local data on dosing and safety.

South Korea: GI Innovation’s GI-301 (YH35324, Phase 1/2) is a long-acting anti-IgE Fc-fusion biologic (next-gen omalizumab), with early data on rapid IgE reduction; co-developed with Yuhan for monthly dosing. Hanmi Pharmaceutical’s HM43239 (Phase 1) targets mast-cell signaling kinase for allergic diseases including CSU.

Taiwan: OBI Pharma’s OBI-999 platform (early Phase 1) modulates KIT/mast-cell pathways for urticaria-related disorders, focusing on mast-cell depletion.

CSU pipelines emphasize anti-IgE (e.g., GI-301), BTK inhibition (TAS5315), mast-cell depletion/KIT modulation (Taiwanese platforms), and immune signaling kinase modulation (Hanmi).

Coverage: 7MM. Study Period: 2020–2034. Companies: Verigraft AB, enVVeno Medical Corporation, Theraclion, and others. Pipeline Therapies: Coumarin/troxerutin, Antistax film coated tablets, Venocur Triplex®, Antistax®, Detralex, V0322 BC, Esarin Gel, 0.1% TR 987, Sirolimus, and others. Market Dynamics: Drivers, barriers, access, reimbursement, unmet needs, and future perspectives.

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2034

DelveInsight’s “Chronic Spontaneous Urticaria (CSU) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CSU, historical and forecasted epidemiology of CSU in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading Chronic Venous Insufficiency Companies developing therapies include - Verigraft AB, enVVeno Medical Corporation, Theraclion, Philips, BD, MediWound, and others.

Chronic Spontaneous Urticaria- Pipeline Insight, 2025

DelveInsight’s, “Chronic Spontaneous Urticaria- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. The leading Chronic Venous Insufficiency Companies developing therapies include - Verigraft AB, enVVeno Medical Corporation, Theraclion, Philips, BD, MediWound, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com